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 11 
Purpose: To establish whether deep learning methods are able to improve the signal-to-noise 12 
ratio of time-domain (TD) optical coherence tomography (OCT) images to approach that of 13 
spectral-domain (SD) OCT. 14 
Design: Method agreement study and progression-detection in a randomized, double-masked, 15 
placebo-controlled, multi-centre trial for open-angle glaucoma (OAG) [UK Glaucoma Treatment 16 
Study (UKGTS)]. 17 
Participants: Cohort for training and validation: 77 stable OAG participants with TDOCT and 18 
SDOCT imaging at up to 11 visits within 3 months. Cohort for testing: 284 newly-diagnosed OAG 19 
patients with TDOCT from a cohort of 516 recruited at 10 UK centres between 2007 and 2010. 20 
Methods: An ensemble of generative adversarial networks (GANs) was trained on TDOCT and 21 
SDOCT image pairs from the training dataset and applied to TDOCT images from the testing 22 
dataset. TDOCT were converted to synthesized SDOCT images and segmented via Bayesian fusion 23 
on the output of the GANs.  24 
Main Outcome Measures: 1) Bland-Altman analysis to assess agreement between TDOCT and 25 
synthesized SDOCT average retinal nerve fibre layer thickness (RNFLT) measurements and the 26 
SDOCT RNFLT. 2) Analysis of the distribution of the rates of RNFLT change in TDOCT and 27 
synthesized SDOCT in the two treatments arms of the UKGTS was compared. A Cox model for 28 
predictors of time-to-incident VF progression was computed with the TDOCT and the synthesized 29 
SDOCT. 30 
Results: The 95% limits of agreement between TDOCT and SDOCT were [26.64, -22.95], between 31 
synthesized SDOCT and SDOCT were [8.11, -6.73], and between SDOCT and SDOCT were [4.16, -32 
4.04]. The mean difference in the rate of RNFL change between UKGTS treatment and placebo 33 
arms with TDOCT was 0.24 (p=0.11) and with synthesized SDOCT was 0.43 (p=0.0017). The hazard 34 
ratio for RNFLT slope in Cox regression modeling for time to incident VF progression was 1.09 35 
(95% CI 1.02 to 1.21) (p=0.035) for TDOCT and 1.24 (95% CI 1.08 to 1.39) (p=0.011) for synthesized 36 
SDOCT. 37 
Conclusions: Image enhancement significantly improved the agreement of TDOCT RNFLT 38 
measurements with SDOCT RNFLT measurements. The difference, and its significance, in rates of 39 
RNFLT change in the UKGTS treatment arms was enhanced and RNFLT change became a stronger 40 
predictor of VF progression. 41 
Introduction 42 
Open-angle glaucoma is a progressive optic neuropathy in which retinal ganglion cell (RGC) axon 43 
loss, probably as a consequence of damage at the optic disc, causes a loss of vision, 44 
predominantly affecting the mid-peripheral visual field and in the ‘macula vulnerability zone’[1]. 45 
Glaucoma is the leading cause of irreversible blindness worldwide and the second major cause 46 
for blind registration in the UK[2,3]. The vision loss is associated with restricted mobility[4], falls 47 
and motor vehicle accidents[5]. Evaluating the rate of deterioration of the pathology is crucial in 48 
order to assess the risk of functional impairment and to establish sound treatment strategies. 49 
Therefore, accurately monitoring the efficacy of disease-modifying drugs in glaucoma therapy is 50 
of great importance. Clinically, standard automated perimetry (SAP) is employed to assess the 51 
status of the visual field (VF), whereas optical coherence tomography (OCT) is used as a surrogate 52 
measure to evaluate retinal ganglion cell (RGC) loss by measuring retinal nerve fibre layer (RNFL) 53 
thickness around the optic nerve head (ONH).  54 
Evidence that imaging can identify progressive glaucomatous damage has been 55 
extensively reported in literature, recognising the potential of structural measures to support VF 56 
testing[18-25]. Medeiros et al.[26,27] address whether biomarkers, such as IOP and imaging 57 
measurements can be used as valid surrogate endpoints in clinical trials evaluating new therapies 58 
for glaucoma. They suggest that a valid surrogate endpoint must be able to predict a clinically 59 
relevant endpoint, such as loss of vision or decrease in quality of life. Moreover, the authors 60 
propose that the effect of a treatment on the surrogate endpoint must capture the effect of the 61 
treatment on the clinically relevant endpoint. Specifically, imaging biomarkers could potentially 62 
be used in combination with functional outcomes in composite endpoints in glaucoma trials, 63 
overcoming weaknesses of using structural or functional endpoints separately. Studies should be 64 
designed and conducted in such a way that proper validation of potential biomarkers in glaucoma 65 
clinical trials could be demonstrated. Whereas spectral-domain (SD) and swept-source (SS) 66 
optical coherence tomography (OCT) are the state-of-the-art technologies for structural imaging 67 
of anatomy relevant to glaucoma, no large-scale clinical trials have yet employed SD or SS OCT to 68 
monitor glaucoma deterioration. The UK Glaucoma Treatment Study (UKGTS)[15] is the only 69 
glaucoma study to assess the vision-preserving efficacy of a disease-modifying drug with both VF 70 
and OCT outcomes. In the UKGTS, time-domain (TD) OCT was used as the imaging outcome since 71 
SD OCT (SDOCT), which offers better measurement precision, was not in widespread clinical use 72 
at the time of trial initiation. In the initial reports of the UKGTS, the rate of RNFL loss, measured 73 
with TD OCT, was unable to distinguish the treatment groups in the UKGTS and combining TD 74 
OCT and VF information did not improve detection of the treatment effect over the use of VF 75 
information alone[33]. This is most likely a result of the poor signal-to-noise ratio (SNR) and 76 
precision of TDOCT[23, 40].  77 
Meanwhile, various methods for super resolution (SR) using convolutional neural 78 
networks (CNNs), such as generative adversarial networks (GANs), have been proposed to 79 
transform image quality and appearance[28-32]. In medical imaging, GANs have been 80 
successfully employed to address the ill-posed nature of cross-modal synthesis. For example, 81 
GANs have been proposed to predict computed tomography (CT) and positron emission 82 
tomography (PET) images from magnetic resonance imaging (MRI)[28-30]. Concerning signal 83 
enhancement, synthesis has been achieved at different resolution scales and by enforcing cycle-84 
consistency, albeit not focusing on medical applications [31, 32]. These works may, however, 85 
present important limitations for SR in medical imaging. First, due to the restricted view of GANs’ 86 
spatial window, preservation of spatial smoothness and anatomical features in predictions is not 87 
always guaranteed. Second, single GAN predictions are characterized by spatial and intensity 88 
variability. Therefore, in order to extract robust anatomical quantifications from the output of 89 
GANs, principled schemes accounting for prediction uncertainty must be developed. This 90 
requires, for instance, probabilistic modelling of the uncertainty of the underlying signal 91 
distributions on distinct image parts, to preserve anatomical structures and account for spatial 92 
coherency. 93 
This paper evaluates whether deep learning ‘super resolution’ techniques to ‘learn’ 94 
SDOCT images from TDOCT images can improve the signal-to-noise ratio of TD OCT and improve 95 
the performance of TD OCT to identify glaucomatous RNFL changes over time. The motivation 96 
for the work was to improve the image quality of the only existing OCT data set from a large-scale 97 
clinical trial in glaucoma to enable the further exploration of imaging endpoints in future clinical 98 
trials of glaucoma therapy[ref companion piece by editor]. 99 
 100 
Methods 101 
The deep learning algorithm was trained and validated on paired TD and SD OCT images from 102 
one dataset (‘RAPID’) and then tested on the TD OCT images from the UKGTS.  103 
 104 
RAPID 105 
Eighty-two clinically stable glaucoma patients under standard treatment (intraocular pressure 106 
mean 14.0 mmHg [5th to 95th percentile 8.0 to 21.0 mmHg] and VF MD −4.17 dB [5th to 95th 107 
percentile -14.22 to 0.88dB]) were recruited to a test–retest study. Seventy seven (148 eyes) of 108 
the participants recruited attended for up to 10 visits within a 3-month period, for a total of 1256 109 
patient-eye visits. This data set was taken to represent a ‘stable glaucoma’ cohort; assumptions 110 
made include that, over such a short length of time, no clinically meaningful changes in the VF or 111 
RNFL structure would occur and that the variability characteristics of the VF and RNFL 112 
measurements are similar to those seen in clinical practice over longer periods of time. The study 113 
was undertaken in accordance with good clinical practice guidelines and adhered to the 114 
Declaration of Helsinki. The study was approved by the North of Scotland National Research 115 
Ethics Service committee on 27 September 2013 (reference no.: 13/NS/0132) and NHS 116 
Permissions for Research was granted by the Joint Research Office at University College London 117 
Hospitals NHS Foundation Trust on 3 December 2013. All patients provided written informed 118 
consent before the screening investigations were carried out. Recruitment criteria were based 119 
on those for the UKGTS. Patients were required to have reproducible VF loss with corresponding 120 
damage to the ONH and no other condition that could lead to VF loss, be aged > 18 years and 121 
have a visual acuity of ≥	20/40, a refractive error within ± 8 dioptres and an IOP of ≤	30 mmHg. 122 
The VF MD had to be better than –16 dB in the worse eye and better than –12 dB in the better 123 
eye. VF loss was defined as a reduction in sensitivity at two or more contiguous locations with p 124 
< 0.01 loss or more, three or more contiguous locations with p < 0.05 loss or more, or a 10-dB 125 
difference across the nasal horizontal midline at two or more adjacent locations in the total 126 
deviation plot. Participants attended approximately once a week for 10 visits, with VF testing and 127 
OCT imaging carried out twice at the first visit and once at each subsequent visit. VF testing was 128 
undertaken with the Humphrey Field AnalyserTM (HFA) and OCT imaging was carried out using 129 
Stratus TD OCTTM (Carl Zeiss Meditec Inc., Dublin, CA, USA) and Spectralis SD OCT (Heidelberg 130 
Engineering, Heidelberg, Germany) (software version 5.2.4). RAPID participants had slightly more 131 
advanced glaucoma (VF MD −4.17 compared to −2.65 dB) and lower IOP (14.0 compared to 19.0 132 
mmHg) than UKGTS participants. More details can be found elsewhere [33]. 133 
 134 
UKGTS 135 
The UKGTS is a multicentre, randomized, double-masked, placebo-controlled trial assessing 136 
visual function preservation in newly diagnosed open-angle glaucoma (OAG) patients (trial 137 
registration number, ISRCTN96423140). 516 newly-diagnosed (previously untreated) 138 
participants with OAG were prospectively recruited at 10 UK centres between 2007 and 2010. 139 
The observation period was 2 years, with subjects monitored by VF testing, quantitative imaging, 140 
optic disc photography and tonometry at 11 scheduled visits. ONH structure was monitored with 141 
Heidelberg Retina Tomograph at all study sites and with Stratus TD OCTTM(Carl Zeiss Meditec Inc., 142 
Dublin, CA, USA) (software version 5.0) and GDxECC Nerve Fiber Analyzer (Carl Zeiss Meditec Inc., 143 
Dublin, CA, USA) at study sites with those devices. With respect to the whole UKGTS cohort, the 144 
baseline mean IOP (±SD) was 18.9±4mmHg in the better mean deviation (MD) eyes (median [IQR] 145 
MD -1.27dB [-2.37, -0.19]) and 19.9±4.6mmHg in the worse MD eyes (median [IQR] MD -3.30dB 146 
[-5.60, -1.98]). The median (interquartile range) VF MD for all eligible eyes was -2.9 dB (-1.6 to -147 
4.8 dB). 148 
The participants were allocated randomly to receive the IOP-reducing prostaglandin analog 149 
latanoprost (0.005%) or placebo eye drops. The UKGTS, and the subsequent analysis of 150 
anonymized data in this study, adhered to the tenets of the Declaration of Helsinki and was 151 
approved by local institutional review boards (Moorfields and Whittington Research Ethics 152 
Committee on June 1, 2006, ethics approval reference, 09/H0721/56). Study participants 153 
provided written informed consent. A total of 488 from 516 enrolled participants with post-154 
baseline data were analysed in the trial (latanoprost, n=244; placebo, n=244). Out of those, a 155 
subset of 284 participants (143 participants in the placebo group and 141 participants in the 156 
latanoprost group) had adequate quality VF and OCT data, with > 6 months of follow-up, and five 157 
or more visits and with data for both VFs and OCT at the baseline visit. For eye-based analysis, 158 
the eye with the worse MD was used. VF deterioration was the primary end point in the trial; 159 
time to VF deterioration within 24 months. Deterioration (progression) analysis was performed 160 
in the Humphrey Field AnalyserTM (HFA) II-i Guided Progression AnalysisTM (GPA) software 161 
(version 5.1.1) (Carl Zeiss Meditec Inc., Dublin, CA, USA), a sensitive technique that considers 162 
changes at individual test locations in the visual field. Deterioration (progression) criteria and 163 
details of the trial design and trial outcome are published elsewhere[15,33]. In short, the time to 164 
VF deterioration was significantly longer in the treatment group than in the placebo group 165 
(adjusted hazard ratio, 0.44; 95% confidence interval, 0.28 to 0.69).  166 
 167 
Visual Field Measurements 168 
All VF tests were performed with the HFA II (or II-i) and the SITA standard 24-2 program. A reliable 169 
VF was one with a false-positive rate of < 15% and < 20% fixation losses (for fixation losses of > 170 
20%, reliability was based on the subjective judgement of the technician supervising the test and 171 
the clinician reading the test, including an assessment of the eye tracker trace). Unreliable tests 172 
were repeated, either on the same day (with a break of at least 30 minutes) or on a subsequent 173 
occasion. The reference standard analysis for VF deterioration was that used for the outcome of 174 
the UKGTS and was undertaken with the HFA II-i GPA software (version 5.1.1)[15]. 175 
 176 
Spectralis OCT Retinal Nerve Fiber Layer Measurement 177 
In the RAPID study, the circumpapillary RNFL thickness was measured with a 3.5 mm-diameter 178 
scan circle centred on the optic disc with the eye-tracking system activated with Spectralis SD-179 
OCT Heidelberg Eye Explorer (Heidelberg Engineering, Heidelberg, Germany) (software version 180 
5.2.4). Automatic real-time (ART) function was activated, thereby allowing multiple frames, i.e. 181 
B-scans, to be averaged for speckle noise reduction.  182 
 183 
Stratus OCT Retinal Nerve Fiber Layer Measurement 184 
In the RAPID and the UKGTS, the fast RNFL 3.4 scan protocol was used to measure the 185 
parapapillary RNFL with TD Stratus OCTTM (Carl Zeiss Meditec Inc., Dublin, CA, USA) (software 186 
version 5.0). A scan circle of 3.4 mm in diameter consisting of 256 A-scans was positioned 187 
manually at the centre of the optic disc.  188 
Right-hand orientation was used for documentation of clock hour measurements in 189 
SpectralisOCT and StratusOCT and RNFL measurements are provided as means (average RNFL 190 
around the ONH) and in clock-hour sectors. 191 
 192 
Imaging Analysis Protocol and Quality Control 193 
In the original UGKTS analysis, for TDOCT only, the images used followed the fast RNFL protocol: 194 
the OCT instrument software averages the measurements from three images acquired in quick 195 
succession and a signal strength of ≥ 7 was required; images were retaken if necessary. Images 196 
of lower quality, or those with a software alert, were not included in the analyses. As a result, 197 
10,633 (21.3%) OCT scans were excluded in the original UKGTS analysis[40]. In the present 198 
analyses, for TD OCT in the UKGTS and SD and TD OCT in the RAPID, images were excluded only 199 
when our pre-processing algorithm failed; this was based on the success of an algorithm to 200 
estimate the retinal pigment epithelium (RPE) location (which is subsequently used to flatten the 201 
images, as the topology around the optic nerve head undulates). As a result, in the RAPID study, 202 
from 4,902 TD OCT scans, 257 (5.2%) were excluded. From 1,789 SD OCT scans, 68 (3.8%) were 203 
excluded. A patient with N TDOCT and M SDOCT can theoretically produce a maximum of NxM 204 
TD–SD OCT image pairs which can subsequently be used for the learning process on cross-modal 205 
synthesis.  For the UKGTS TDOCT images, all the raw intensity OCT data were used, including each 206 
one of the three individual sequential ‘fast’ circular scans which are used for averaging, and 207 
images with any signal strength were accepted for application of our algorithm and further 208 
analysis. As a result, a total of 36,169 (31.6%) TDOCT individual scans failed the RPE detection 209 
algorithm. Note that patients were not excluded because of poor scan quality (as determined by 210 
the OCT software) since those scans could theoretically become scans with good quality after 211 
image enhancement. Analysis was based on participants who had 15 (3 x 5) or more raw images, 212 
i.e. five averaged images.  213 
 214 
Analysis 215 
Image Synthesis. We use cyclical GANs[32,34] to infer morphological descriptors from low to 216 
high quality anatomical information. OCT images have a very specific geometry where the 217 
background, i.e. vitreous cavity, is clearly separated from the retinal layers at the ILM. Thus, we 218 
used image stitching, exploiting the ILM identification, to separate background from layer signal. 219 
Moreover, cycle GANs require a fixed window on which spatial filters and mappings are learned. 220 
However, since OCT signal and noise properties are characterized by different spatial scales, a 221 
modality transfer method based on a fixed spatial window might not be able to capture all the 222 
necessary spatial information needed for synthesis. This reduces the chance for cross-modal 223 
distributions to share supports in latent space. To address this problem, we propose an ensemble 224 
of spatially coherent cycle GANs[32] to learn the TDOCT-to-SDOCT mapping and to translate a 225 
TDOCT into a synthesized SDOCT image. The scheme is the following. Each GAN is trained by 226 
employing a different spatial window size: 128 x 128, 256 x 256 or 512 x 512, learning a mapping 227 
from the observed TDOCT image ITD and random noise vector z, to the target SDOCT image ISD, 228 
G: {ITD, z} →	ISD. As a result, we train six GANs: three with background pairs and three with retinal 229 
layer pairs. The synthesized backgrounds and layers are stitched back according to the window 230 
size, i.e. I128x128, I256x256, I512x512, and the average synthesized stitched image 𝑰' is obtained. To 231 
preserve the morphological correlation between training pairs, cycle GANs were trained with 232 
windows centered at the same geometrical location in both pairs. This deep learning technique 233 
is based on learning the representation between TD and SD OCT using 24,792 paired examples. 234 
The transfer mapping is learned in an independent dataset, i.e. the RAPID dataset, which contains 235 
pairs of both modalities, and the method is applied to the UKGTS dataset, enhancing the TD OCT 236 
images via quality transfer from SD OCT. TD OCT images are converted to ‘synthesized SD OCT’ 237 
images and segmented via an ensemble of GANs: for each TD OCT, we produce three SD OCT 238 
candidates. Fig. 1 shows the proposed framework for OCT synthesis via the ensemble of GANs. 239 
The final RNFL segmentation is obtained on the average synthesized image of the segmented SD 240 
OCT candidates from each of the three GANs in the ensemble via the effective Bayesian label-241 
propagation of multi-atlas segmentation (MAS)[36]. For segmentation, we adopted the layer 242 
segmentation model of Mayer et al.[37]. For label fusion of the three segmented synthesized SD 243 
OCT candidates, we used, as atlases, their segmented RNFL sections and the original TD OCT RNFL 244 
segmentation.  We registered the retinal layers of the atlases, using the method described by Du 245 
et al. [38], in the average synthesized image (average of three SD OCT candidates). The Spectralis 246 
SD OCT images were segmented with the same software as that we used for the ‘synthesized SD 247 
OCT’ images. The intuition is that if we can produce realistic SD OCT images, an off-the-shelf 248 
segmentation model should output the same RNFL thickness as obtained with the original data. 249 
Note that the segmentation model of Mayer et al.[37] failed in segmenting TDOCT images. As a 250 
result, the original StratusOCT segmentation was used for TDOCT images. The technical details 251 
of the method are described in Lazaridis et al.[41].  252 
 253 
 254 
Statistical Analysis and Evaluation. We quantified the quality improvement of the ‘synthesized 255 
SD OCT’ images over the original TD OCT images in both the RAPID and UKGTS data sets. Fig. 2 256 
shows an example of a SDOCT image synthesized from a TDOCT image. Fig. 2a and Fig. 2b 257 
constitute the original TDOCT-SDOCT pair of images, whereas Fig. 2c is the synthesized SDOCT 258 
after modality transfer and synthesis. To compare the performance of the Cox models, i.e. Cox 259 
model before and after TDOCT image enhancement, we calculate the rank-based Somers’ D 260 
between predicted risk scores and observed survival times. We compare the rankings of rate of 261 
RNFL loss and time-to-VF progression per patient across the dataset and we assess their 262 
agreement. Somers’ D takes values between -1 when all ranking pairs disagree and 1 when all 263 
pairs agree. To estimate the standardized effect size for the same population before and after 264 
TDOCT image enhancement, we calculate Cohen’s D using the difference in the rates of loss 265 
between the treatment groups. Although there are no reference values for Cohen’s standardized 266 
Figure 1: SDOCT synthesis via ensemble of GANs. Box A: Backgrounds are painted black. Box B: Three 
GANs are trained with layer pairs. Synthesized images are stitched back with the backgrounds and the 
average synthesized stitched image is obtained. Separation of layers and background is illustrated with 
scissors. 
effect size measures, d = 0.2, 0.5 and 0.8 provide a conventional reference frame, corresponding 267 
to small, medium and large effects [43]. 268 
 269 
 270 
RAPID data set: we compared the agreement of the average RNFL thickness derived from i) the 271 
Stratus TD OCT software and ii) the ‘synthesized SDOCT’ (described above) with the paired 272 
Spectralis SD OCT average RNFL thickness with Bland Altman plots. To give context, we also 273 
present the agreement between SD OCT RNFL thickness measurements acquired on different 274 
days – this represents the ‘ceiling’ one would expect to see if synthesized SD OCT images were 275 
exactly the same as real SD OCT images.  276 
UKGTS data set: we compare the ability of the rate of RNFL loss measured with Stratus TD OCT 277 
and synthesized SD OCT to distinguish the treatment arms of the trial (Mann Whitney test). The 278 
effect size is estimated with Cohen’s D. We also present the respective strength of association of 279 
the rate of RNFL change with time to VF progression in a Cox proportional hazards model. 280 
 281 
Results 282 
Test-retest variability, summarized by the standard deviation of repeat measurements over the 283 
first three visits across all subjects of the RAPID study, was lower for the Synthesized SDOCT than 284 
for the original TDOCT data (Table 1). Table 1 also shows the 95% limits of agreement (LOA) and 285 
Figure 2: OCT synthesis results via fusion of GANs. (a) and (b) illustrate a pair of TDOCT and SDOCT 
images. (c) Synthesized SDOCT from (a). 
the mean difference between RNFL measurements. The 95% limits of agreement between TDOCT 286 
and SDOCT were [26.64, -22.95], between synthesized SDOCT and SDOCT were [8.11, -6.73], and 287 
between SDOCT and SDOCT were [4.16, -4.04]. Fig. 3 illustrates the corresponding Bland-Altman 288 
agreement plots of the RNFL measurements made from the segmented synthesized OCT images 289 
with respect to the ‘ground truth’ Spectralis SD OCT RNFL measurements derived with the same 290 
segmentation algorithm (RAPID data set). Table 2 presents the mean and the range of RNFL loss 291 
rates for TDOCT and synthesized SDOCT images. Table 3 and Table 4 illustrate the Cox 292 
proportional hazards model fitted to the time to VF progression for TD OCT and synthesized SD 293 
OCT. The hazard ratio for RNFLT slope in Cox regression modelling for time to incident VF 294 
progression was 1.09 (95% CI 1.02 to 1.19) (p=0.035) for TDOCT and 1.24 (95% CI 1.11 to 1.39) 295 
(p=0.011) for synthesized SDOCT. Fig. 4 illustrates the VF mean sensitivity (MS) change in decibels 296 
per year and the distribution of rate of RNFL thickness change for the subset of UKGTS 297 
participants with OCT images. Fig. 4b is generated from the original TD OCT whereas Fig. 4c from 298 
the synthesized SDOCT data. The placebo group had faster rates of deterioration than the 299 
latanoprost group in both cases. For the original TD OCT UKGTS data, the difference in 300 
distribution of slopes was not statistically significant (Mann-Whitney U Test, p = 0.08). For the 301 
synthesized SD OCT, the difference was statistically significant (Mann-Whitney U Test, p = 302 
0.0017). Table 5 illustrates the corresponding effect sizes (Cohen's D), with confidence intervals. 303 
It can be seen that Cohen’s D for synthesized SD OCT is closer to Cohen’s D for VFs than that for 304 
TD OCT, indicating a modest improvement in effect size. Table 6 compares the predictive power 305 
of the two Cox models; we calculate the rank order statistic Somers’ D with confidence limits[42]. 306 
It can be observed that Somer’s D is higher for the Cox model with synthesized SD OCT, indicating 307 













Figure 3: Bland-Altman plots on the agreement between time domain and synthesized spectral 
domain OCT RNFL measurements versus the ‘real’ spectral domain OCT RNFL measurements on the 
RAPID dataset. The proposed method leads to significantly better agreement. 
Figure 4: (a) Distribution of the rate of VF mean sensitivity (MS) change in decibels per year for the subset 
of UKGTS participants with OCT images (placebo, n = 131 participants; latanoprost, n = 127 participants). 
Bottom: Distribution of the rate of OCT RNFL thickness change for the subset of UKGTS participants with 
OCT images. (b) Original UKGTS TDOCT data (placebo, n = 131 participants; latanoprost, n = 127 









Covariate  b  SE  Wald  p  Exp(b)  95% CI of Exp(b)  
Age  0.018  0.014  1.748  0.186  1.018  0.991 to 1.045  
Allocation  -0.770  0.287  7.226  0.007  0.463  0.264 to 0.812  
Baseline IOP  0.050 0.029  2.972  0.085  1.051  0.993 to 1.113 
Baseline VF MD  0.086  0.048  3.123  0.077  1.089  0.991 to 1.198 
OCT RNFL slope  0.086  0.041  4.430  0.035  1.089  1.031 to 1.412 
Disc haemorrhage  0.576  0.283  4.143  0.042  1.779  1.022 to 3.099 
 328 
Method  Synthesized SDOCT StratusOCT SpectralisOCT 
95% LOA   [8.11, -6.73]  [26.64, -22.95] [4.16, -4.04] 
Mean Diff.   0.69  1.84 0.06 
Mean SD   1.29  2.67 0.77 
Method StratusOCT Synthesized SD OCT  
Treatment  Placebo  Treatment  Placebo  
Mean (SD) (μm/year) 
 
-0.15 (3.971)  -0.39 (4.139)  -0.83 (2.6116)  -1.26 (2.6720)  
Diff. in mean rate (95% CI)  0.24 (-0.837 to 0.672)  0.43* (0.0279 to 0.8321)  
p-value 0.08 0.0017 
 
  
Table 1: Limits of agreement and mean difference between time domain, synthesized spectral domain, 
‘real’ spectral domain OCT RNFL measurements versus the ‘real’ spectral domain OCT RNFL 
measurements. The mean SD gives the standard deviation of the first three test-retest visits for both eyes. 
SDOCT = spectral domain optical coherence tomography; TDOCT = time domain optical coherence 
tomography 
. 
Table 2: Comparison of rate of RNFL change in Stratus OCT and synthesized spectral domain OCT in the 
UKGTS data set. The significance of the difference between treatment and placebo progression rates 
was calculated with the Mann Whitney U test. SDOCT = spectral domain optical coherence tomography; 
TDOCT = time domain optical coherence tomography 
 
Table 3: Cox proportional hazards model for time to incident VF progression in the UKGTS with the original 
TD OCT images. Note b = regression coefficient, Wald statistic = (b/SE)2, p = p-value associated with the 





Covariate  b  SE  Wald  p  Exp(b)  95% CI of Exp(b)  
Age  0.021  0.009  5.444  0.113  1.021  0.922 to 1.152  
Allocation  -0.586  0.195  9.030  0.001  0.608  0.315 to 0.901  
Baseline IOP  0.106  0.089  1.418  0.109  1.111  0.811 to 1.429 
Baseline VF MD  0.041  0.022  3.473  0.062  1.041  0.883 to 1.312 
OCT RNFL slope  0.218  0.008  7.425  0.011  1.244  1.105 to 1.394 












Modality  Synthesized SDOCT StratusOCT Visual Fields 
Cohen’s D  0.256 0.223 0.491 
95% CI  [0.126, 0.487]  [0.076, 0.535] [0.289, 0.652] 
p-value   0.03 0.05 0.002 
Model  Synthesized SDOCT StratusOCT 
Somers’ D  0.326  0.289 
95% CI  [0.113, 0.581]  [0.129, 0.448] 
p-value    0.019 0.009  
Table 4: Cox proportional hazards model for time to incident VF progression in the UKGTS with the  
synthesized SD OCT images. Note b = regression coefficient, Wald statistic = (b/SE)2, p = p-value associated 
with the Wald statistic and Exp(b) = the hazard ratio. (placebo, n = 131 participants; latanoprost, n = 127 
participants). 
 
Table 5: Comparison of treatment groups effect size for each modality. Cohen’s D is calculated as measure 
of parametric group testing, measuring the effect size. SDOCT = spectral domain optical coherence 
tomography; TDOCT = time domain optical coherence tomography; CI = confidence interval. 
 
Table 6: Comparison of the predictive power of Cox models. Somers’ D is calculated as measure of the 
ordinal predictive power of each model. Confidence intervals and p-values for the predictive powers of 
each model are also computed. SDOCT = spectral Table 6: Comparison of the predictive power of Cox 
models. Somers’ D is calculated between predicted risk scores and observed survival times. Confidence 
intervals and p-values for the predictive powers of each model are also computed. SDOCT = spectral 
domain optical coherence tomography; TDOCT = time domain optical coherence tomography; CI = 
confidence interval. 




In this work, we demonstrate that a super resolution deep learning method applied to TD OCT 343 
images significantly improves the signal-to-noise ratio of the images, as quantified by the 344 
agreement of segmented RNFL thickness measurements with SD OCT measurements, and 345 
significantly reduces test-retest variability (Table 1, Figure 3) and the improves the ability of rates 346 
of RNFL loss to separate the treatment arms of the UKGTS. When the rate of RNFL loss in the 347 
UKGTS data set is calculated from the ‘synthesized SD OCT’ images (Table 2), the difference in 348 
RNFL slope measurements is able to distinguish the treatment groups (Mann-Whitney U Test, p 349 
= 0.0017).  350 
The ensemble of GANs approach produced segmented RNFL thickness values more consistent 351 
with the ground truth SD OCT values than the TD OCT, as demonstrated by narrower limits of 352 
agreement (Figure 3, Table 1), and reduced the test retest variability in the measurements by 353 
half, as demonstrated by the smaller standard deviation of repeat measurements (Table 1). The 354 
Bland–Altman plots revealed proportional biases in the evaluation of agreement between SD OCT 355 
and TD OCT, and between SD OCT and synthesized SD OCT RNFL measurements in the RAPID 356 
study data set, suggesting that there may be a calibration difference, possibly related to the 357 
inherent characteristics of the OCT instruments. These findings are in agreement with Leung et 358 
al.[22], where the same proportional bias was reported between Cirrus SD-OCT and Stratus TD 359 
OCT. 360 
When the super resolution method was applied to an independent test data set, from the UKGTS, 361 
the better separation of the treatment arms evidenced the data quality improvement. The 362 
analysis of the capability of TD OCT images to distinguish the UKGTS treatment arms showed 363 
that, although the rate of RNFLT loss was faster in the placebo-treated eyes, the difference from 364 
the latanoprost-treated eyes did not reach statistical significance (Table 2; Figure 4b). In contrast, 365 
the same analysis with the synthesized SD OCT images demonstrated a statistically significant 366 
difference between treatment and placebo progression rates (MannWhitney U Test, p = 0.0017 367 
(Table 2; Figure 4c). The difference between treatment groups in the rate of RNFL thinning 368 
(synthesized SD OCT) is closer to the difference between groups for the rate of VF MD 369 
deterioration (Figure 4) than for the TD OCT analysis (Table 5).  Our analysis further illustrates 370 
that the SD OCT imaging of RNFL may provide a sufficiently high precision for longitudinal 371 
assessment of RNFL changes, as low measurement variability is a prerequisite for detecting 372 
change during longitudinal analysis (Table 6); improving the longitudinal SNR. 373 
Further evidence for the improvement in data quality comes from the Cox proportional hazards 374 
model which was fitted to the time to VF progression original UKGTS data (Table 3). This 375 
demonstrated that treatment allocation, the occurrence of a disc haemorrhage during follow-up 376 
(either eye) and the rate of TD OCT RNFL change were significantly associated with survival. Pre-377 
treatment IOP and baseline VF MD approached statistical significance (p between 0.077 and 378 
0.085); the overall model fit was significant (p = 0.0007). The same model was fitted after TD OCT 379 
signal enhancement (Table 4) and showed a greater level of significance in the overall fit of the 380 
model (p = 0.0001). The significance of the association of treatment allocation, occurrence of a 381 
disc haemorrhage during follow-up (either eye) and rate of OCT RNFL change with time to VF 382 
deterioration also improved, with a larger hazard ratio for RNFL change.  383 
 384 
 385 
Study weaknesses and further work 386 
In this work, we have used randomised controlled trial data coming from the first large scale 387 
glaucoma trial with OCT data, i.e. the UKGTS. We further presented a super resolution approach 388 
to translate a TD OCT image into a synthesized SD OCT image. The image-enhancement approach 389 
is based on state-of-the-art image synthesis and semi-automated segmentation of the resulting 390 
synthesized SDOCT images, integrating label fusion and deep learning. The proposed 391 
methodology appears robust and flexible both in terms of architecture and label fusion. Since the 392 
training dataset is large and of high resolution, training of each individual model takes a lot of 393 
time, making the method computationally expensive for training. This, limitation, is however a 394 
negligible problem in practice as the algorithm can be run offline. As the agreement of 395 
synthetized SD OCT RNFL measurements with real SD OCT RNFL measurement did not reach the 396 
level of agreement indicated by the limits of agreement for repeat real SD OCT RNFL 397 
measurements, this study likely underestimates the potential utility of SD OCT imaging in future 398 
trials. 399 
The TD OCT images were segmented with the proprietary instrument software and the real and 400 
synthesized SD OCT images with a publicly-available algorithm; we did not have access to the 401 
proprietary algorithm to apply to SD OCT images and the publicly-available algorithm failed on 402 
the TD OCT images. Therefore, the results we report relate to comparisons of the compound 403 
‘image + segmentation algorithm’. 404 
 405 
Future work will focus on combining SD OCT RNFL rates of change to VF rates of change, in a 406 
similar way as that done for TD OCT[40], to see whether the addition of the imaging data 407 
improves study power over the use of VF data alone. The motivation is that although the signal-408 
to-noise ratio in the TD OCT UKGTS data is too poor to draw conclusions with respect to disease 409 
deterioration, the synthesized SD OCT data provided some evidence that imaging outcomes 410 









In clinical trials with a vision function outcome, variability in measurements results in the 420 
requirement for large numbers of patients observed over long intervals. As a result, new 421 
beneficial treatments to patients may be delayed and may not be evaluated as trials become 422 
more costly. It is well established that imaging measurements of structural damage to the ONH 423 
are associated with VF loss in glaucoma. Furthermore, imaging measurements are often 424 
considered more precise than VF measurements, making them attractive as potential surrogate 425 
outcomes for clinical trials and clinical practice. The OCT data available in the UKGTS were from 426 
the TD OCT, with poor signal-to-noise characteristics. Previous analysis of the OCT data failed to 427 
distinguish the treatment arms[40]. Here, we show that a super resolution deep learning method 428 
was able to considerably improve data quality, demonstrated by better agreement of RNFL 429 
measurements from synthesized SD OCT images, compared with their source TD OCT images, 430 
with RNFL measurements from actual SD OCT images. When applied to an independent data set 431 
from the UKGTS, the data quality improved to the extent that imaging measurements were able 432 
distinguish treatment groups. These findings suggest that a benefit to trial power can be achieved 433 
by a) further increase the resolution of SDOCT using SR methods b) ensemble methods to 434 
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